{
    "nctId": "NCT05266105",
    "briefTitle": "A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients",
    "officialTitle": "A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Incidence of Dose Limiting Toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed and evaluable locally advanced or metastatic breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must not have received prior oral endocrine or targeted therapy \u2264 2 weeks prior to first dose\n* Must not have received prior chemotherapy, antibody therapy, or investigational therapy \u2264 4 weeks prior to the first dose\n* Prior radiotherapy must have been completed 2 weeks prior to first dose\n* Adequate safety laboratory tests\n* Willingness to use effective contraception\n\nExclusion Criteria:\n\n* Gastrointestinal disease\n* Significant hepatic disease\n* Significant cardiovascular disease\n* Significant ECG abnormalities\n* History of pulmonary embolism or high risk of thrombosis\n* Known HIV infection\n* Active infection (requiring antimicrobial therapy)\n* Pregnant",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}